Gavin Constantine Michael
First SEC filing: Feb. 17, 2022 · Latest: Feb. 17, 2022
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 18, 2024 | BKKT | A | 211,670 | · | · | 2,482,960 Direct | +9.32% | Acquired | (price as of 2026-10-02) |
| March 18, 2024 | BKKT | A | 37,062 | · | · | 2,520,022 Direct | +1.49% | Acquired | (price as of 2026-10-02) |
| March 18, 2024 | BKKT | A | 366,188 | · | · | 2,886,210 Direct | +14.53% | Acquired | (price as of 2026-10-02) |
| March 18, 2024 | BKKT | A | 1,332,456 | · | · | 4,218,666 Direct | +46.17% | Acquired | (price as of 2026-10-02) |
| Feb. 22, 2024 | BKKT | F | 93,591 | $0.96 | $89,847 | 2,271,290 Direct | -3.96% | Disposed | -67.7% (price as of 2026-10-02) |
| Feb. 7, 2024 | BKKT | F | 67,198 | $1.42 | $95,421 | 2,364,881 Direct | -2.76% | Disposed | -78.2% (price as of 2026-10-02) |
| Jan. 25, 2024 | BKKT | F | 384,734 | $1.39 | $534,780 | 2,432,079 Direct | -13.66% | Disposed | -77.7% (price as of 2026-10-02) |
| April 17, 2023 | BKKT | A | 520,500 | · | · | 3,063,914 Direct | +20.46% | Acquired | (price as of 2026-10-02) |
| April 17, 2023 | BKKT | A | 91,137 | · | · | 3,155,051 Direct | +2.97% | Acquired | (price as of 2026-10-02) |
| April 17, 2023 | BKKT | F | 287,838 | $1.47 | $423,122 | 2,867,213 Direct | -9.12% | Disposed | -78.9% (price as of 2026-10-02) |
| April 17, 2023 | BKKT | F | 50,400 | $1.47 | $74,088 | 2,816,813 Direct | -1.76% | Disposed | -78.9% (price as of 2026-10-02) |
| April 17, 2023 | BKKT | A | 520,500 | · | · | 3,063,914 Direct | +20.46% | Acquired | (price as of 2026-10-02) |
| April 17, 2023 | BKKT | A | 91,137 | · | · | 3,155,051 Direct | +2.97% | Acquired | (price as of 2026-10-02) |
| Feb. 24, 2023 | BKKT | A | 391,645 | · | · | 2,463,414 Direct | +18.90% | Acquired | (price as of 2026-10-02) |
| Feb. 24, 2023 | BKKT | A | 80,000 | · | · | 2,543,414 Direct | +3.25% | Acquired | (price as of 2026-10-02) |
| Feb. 24, 2023 | BKKT | A | 587,467 | · | · | 2,659,236 Direct | +28.36% | Acquired | (price as of 2026-10-02) |
| Feb. 24, 2023 | BKKT | A | 80,000 | · | · | 2,739,236 Direct | +3.01% | Acquired | (price as of 2026-10-02) |
| Feb. 10, 2023 | BKKT | F | 67,198 | $1.64 | $110,205 | 2,071,769 Direct | -3.14% | Disposed | -81.1% (price as of 2026-10-02) |
| Feb. 3, 2023 | BKKT | F | 307,580 | $2.00 | $615,160 | 2,138,967 Direct | -12.57% | Disposed | -84.5% (price as of 2026-10-02) |
| Feb. 1, 2023 | BKKT | S 10b5-1 | 340,002 | $1.59 | $540,603 | 2,446,547 Direct | -12.20% | Disposed | -80.5% (price as of 2026-10-02) |
| April 15, 2022 | BKKT | F | 353,998 | $4.64 | $1,642,551 | 2,786,549 Direct | -11.27% | Disposed | -93.3% (price as of 2026-10-02) |
| Feb. 15, 2022 | BKKT | A | 364,547 | · | · | 3,140,547 Direct | +13.13% | Acquired | (price as of 2026-10-02) |
| Jan. 21, 2022 | BKKT | A | 2,082,000 | · | · | 2,776,000 Direct | +300.00% | Acquired | (price as of 2026-10-02) |
| Dec. 21, 2021 | BKKT | A | 694,000 | · | · | 694,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $157,247 | · | $2,415,051 | · | · | · | $1,280,083 | $3,852,381 |
| 2023 | $500,000,500,000 | $250,000,250,000 | $69,803,520,683,367 | · | · | · | $281,076,937 | $147,614,221,440,304 |
| 2022 | $500,000,471,153 | · | $206,833,676,370,920 | · | · | · | $6,937,447 | $214,403,047,884,520 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.